A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours-Reference-Cited by-同舟云学术

A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours

Published:2002-07 Issue:2-3 Volume:1587 Page:215-223
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

Jackman Ann L,Melin Camille J,Kimbell Rosemary,Brunton Lisa,Aherne G.Wynne,Theti Davinder S,Walton Mike

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference29 articles.

1. Molecular regulation of expression of thymidylate synthase;Chu,1999

2. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer;Jackman;Eur. J. Cancer,1995

3. Management of colorectal cancer: defining the role of raltitrexed;Matheson;Dis. Manag. Health Outcomes,2001

4. The cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase;Jackman;Clin. Cancer Res.,1997

5. ZD9331: preclinical and clinical studies;Boyle,1999

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth;Vitamins and Hormones;2018

2. Bacterially-Derived Nanocells for Tumor-Targeted Delivery of Chemotherapeutics and Cell Cycle Inhibitors;Cell Cycle;2007-09

3. Thymidylate Synthase;xPharm: The Comprehensive Pharmacology Reference;2007

4. Fluorine in medicinal chemistry: A review of anti-cancer agents;Journal of Fluorine Chemistry;2006-03

5. Trouble with Potassium Carbonate and Centrifuges: Mass Transfer and Scale-Up Effects in the Manufacture of ZD9331 POM Quinacetate;Organic Process Research & Development;2005-11-15